#Obesity medicine

Chronic weight management as a clinical specialty.

An indirect comparison favoured semaglutide on one MASH endpoint but cannot replace a randomized head-to-head trial.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.

A preclinical mouse study found more fat loss with vutiglabridin plus semaglutide, but it provides no evidence of human efficacy.

A Phase III trial found HD1916 met its prespecified equivalence criterion against reference semaglutide for weight change at 44 weeks.

A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.

A six-trial meta-analysis linked GLP-1-based therapies to fewer apnea events, but high heterogeneity limits the pooled estimate.

REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.

A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.

A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.

A matched UK cohort linked tirzepatide use to lower weight, HbA1c and insulin needs in type 1 diabetes, but it was not randomized.

A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.